Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Laser Incubator Developed for Rapid Blood Group Typing

By LabMedica International staff writers
Posted on 01 Oct 2019
Blood transfusion is a critical treatment for a variety of hematological conditions, including cancer chemotherapy, sickle cell disease treatments, bleeding trauma, including childbirth, and major surgery.

Over 21 million blood components are transfused in the USA alone every year; each having the potential for fatal hemolytic transfusion reactions if recipient and donor are not accurately matched. More...
Identification of antigens and antibodies often requires incubation at human body temperature of 37 °C. Depending on the method, this incubation step can take 5 to 30 minutes.

Chemical Engineers at Monash University (Clayton, Australia) and their colleagues at Haemokinesis (Hallam, Australia) developed rapid optical heating via laser, where targeted illumination of a blood-antibody sample in a diagnostic gel card is converted into heat, via photothermal absorption. The laser-incubator heats the 75 µL blood-antibody sample to 37 °C in less than 30 seconds.

Whole blood samples were stored by refrigeration at 4 °C with ethylenediaminetetraacetic acid (EDTA) as anticoagulant and were used within two weeks post-collection. Reagent red blood cell solutions (Haemokinesis: Stargel10 3 cell screen,) were used for all RBC-antibody incubation tests. Immunoglobulin-G (IgG) anti-D antibody was used for all antibody tests except for the sensitivity control test. The RBC-antibody mixtures were prepared directly in the gel card wells (Haemokinesis Stargel10 AHG System). The gel card heating block (Prototype #5, Haemokinesis) has a fixed temperature of 37 °C. Temperature was detected during incubation directly inside the sample volume in a gel card well using a thermocouple probe.

The team showed that red blood cells act as photothermal agents under near-infrared laser incubation, triggering rapid antigen-antibody binding. They detected no significant damage to the cells or antibodies for laser incubations of up to fifteen minutes. They demonstrate laser-incubated immunohaematological testing to be both faster and more sensitive than current best practice, with clearly positive results seen from laser incubations of just 40 seconds.

Clare A. Manderson, PhD, the first author of the study, said, “Giving blood transfusions to people isn't as simple as giving O-negative to anybody. The 'universal donor' of O-negative blood can seriously harm a lot of people, even kill them. The world of pre-transfusion of blood group typing is huge, and it's really important that it's done quickly and accurately to help save lives.” The study was originally published online on August 2, 2019, in the journal Scientific Reports.

Related Links:
Monash University
Haemokinesis


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.